Pfizer will invest €90.5 million in Valneva

Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15

20-Jun-2022 - Valneva SE and Pfizer Inc. announced that they have entered into an Equity Subscription Agreement and have updated the terms of their Collaboration and License Agreement for Lyme disease vaccine candidate VLA15. As previously announced on April 26, 2022, Pfizer plans to initiate the Phase 3 study ...

EIB grants loan to Valneva

€ 25 Million Loan for research and development of vaccines

13-Jul-2016 - Valneva SE, a pure play vaccine company, and the European Investment Bank (EIB), the world’s largest multilateral bank, announced that the EIB granted Valneva a €25 million loan facility to support its vaccine R&D activities. Valneva plans to use the EIB financing to support the research and ...

Valneva Signs an Agreement to Acquire Dukoral Vaccine

05-Jan-2015 - Valneva SE announced that it has entered into a Sale and Purchase Agreement with Crucell Holland B.V. to acquire Crucell Sweden AB and all assets, licenses and privileges related to Dukoral®, a vaccine against cholera and traveler’s diarrhea caused by ETEC, as well as a Nordics vaccine ...

Valneva Announces Start of Phase II Clinical Trial of its Clostridium difficile vaccine candidate

19-Dec-2014 - Valneva SE announced the initiation of the Phase II clinical trial of its VLA84 prophylactic vaccine candidate against Clostridium difficile (C. difficile), the main cause of nosocomial diarrhea. Data from the Phase I study in healthy elderly and adults showed good safety and immunogenicity of ...

Valneva and BliNK Therapeutics Launch of New Biotech Company

New company has already secured first round of financing

15-Dec-2014 - Valneva SE and BliNK Therapeutics Ltd announced the creation of a private company specialized in the discovery of monoclonal antibodies to be headquartered in Lyon, France and to be named BliNK Biomedical SAS. The new company, which will benefit from the combination of two validated antibody ...